Kurzfassung

Subjects with a confirmed diagnosis of multiple myeloma and measurable secretory disease. Additionally, subjects must have documented disease progression during or after an initial response to at least 1 but no more than 3 prior lines of therapy or have no response to previous treatment (primary refractory disease). Subjects previously treated with bortezomib, and subjects who failed prior therapy
with high-dose dexamethasone will be excluded.